High cost of Xtandi, treatment for prostate cancer, could be solved using “March-In” rights

Federal government is urged to take action on drug prices for key treatment for prostate cancer

It's been one year since four patients living with prostate cancer asked the federal government to use its "March-In" rights to bring down the costs of Xtandi. We're still waiting for an answer. PIRG followed up with this request.

Old fashioned typewriter
Florian Klauer on Unsplash " target="_blank">Florian Klauer | Unsplash.com
Typewriter and letter
Topics
Authors

Patricia Kelmar

Senior Director, Health Care Campaigns, PIRG

Patricia directs the health care campaign work for U.S. PIRG and provides support to our state offices for state-based health initiatives. Her prior roles include senior director of health policy with the National Consumers League, senior policy advisor at NJ Health Care Quality Institute, and consumer advocate at NJPIRG. She serves on the board of the Patient and Caregiver Engagement Advisory Group for the National Quality Forum. Patricia enjoys walks along the Potomac and sharing her love of books with her friends and family around the world.

Find Out More